27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Among older adults at risk of cognitive decline and dementia, a structured, higher-intensity intervention had a statistically significant greater benefit on global cognition compared with an unstructured, self-guided intervention. 5 key findings →
Participants: 1,056 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
During follow-up, 271 participants with MCI were diagnosed with AD and 59 with other dementias. 2 key findings →
Design: cohort study Participants: 750 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this systematic review and meta-analysis of randomized clinical trials of patients with primarily noncancer illness, palliative care, compared with usual care, was statistically significantly associated with less acute health care use and modestly lower symptom burden, but there was no significant difference in quality of life. 4 key findings →
Design: systematic review Participants: 4,068 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among patients with agitated delirium receiving mechanical ventilation in the intensive care unit, the addition of dexmedetomidine to standard care compared with standard care alone (placebo) resulted in more ventilator-free hours at 7 days. 5 key findings →
Participants: 39 Evidence: high
Full summary, score breakdown and related studies → Original source
This is the pivotal Phase 3 trial for donanemab in 1,736 people with early symptomatic Alzheimer's. Donanemab slowed decline on a combined cognitive/functional scale (iADRS) by about 22-35% relative to placebo over 76 weeks, depending on tau levels at baseline. 3 key findings →
Design: phase-3-trial Participants: 1,736 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 1736 randomized participants (mean age, 73.0 years; 996 [57.4%] women; 1182 [68.1%] with low/medium tau pathology and 552 [31.8%] with high tau pathology), 1320 (76%) completed the trial. 3 key findings →
Design: clinical trial Participants: 860 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a significant public health challenge and may have greater incidence among older adults from underrepresented racial and ethnic minority groups. 4 key findings →
Design: cohort study Participants: 90 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among older patients with type 2 diabetes, a history of severe hypoglycemic episodes was associated with a greater risk of dementia. 5 key findings →
Design: cohort study Participants: 16,667 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 275 patients, 51 (18.5%) had persistent coma and died in the hospital. 2 key findings →
Design: cohort study Participants: 275 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Greater consumption of caffeinated coffee and tea was associated with lower risk of dementia and modestly better cognitive function, with the most pronounced association at moderate intake levels. 5 key findings →
Design: cohort Participants: 131,821 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this exploratory analysis, the APOE ε3[R145C] missense variant was associated with an increased risk of AD among individuals of African ancestry with the ε3/ε4 genotype. 5 key findings →
Design: case-control Participants: 31,929 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A program of counseling and support can substantially increase the time spouse-caregivers are able to care for AD patients at home, particularly during the early to middle stages of dementia when nursing home placement is generally least appropriate. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function. 5 key findings →
Participants: 89 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among the 445 participants (243 with normal amyloid, 202 with elevated amyloid), mean (SD) age was 74.0 (5.9) years, mean education was 16.4 (2.7) years, and 52% were women. 2 key findings →
Design: longitudinal study Participants: 243 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of the 120 participants (mean age, 71.4 [SD, 8.6] years; 55% were female), 93 (77.5%) completed the trial. 1 key finding →
Design: phase-2-trial Participants: 120 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
The mean age was 74.2 years (SD, 8.3 years), 48% were women, 23% had subjective cognitive decline, 44% had mild cognitive impairment, and 33% had dementia. 2 key findings →
Participants: 307 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The mean (SD) time between the date of randomization into WHI and the last Modified Mini-Mental State Examination (3MSE) for all WHIMS participants was 4.05 (1.19) years. 5 key findings →
Participants: 2,229 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Compared with the reference standard for diagnosing delirium, 2 study nurses using the CAM-ICU had sensitivities of 100% and 93%, specificities of 98% and 100%, and high interrater reliability (kappa = 0.96; 95% confidence interval, 0.92-0.99). 3 key findings →
Design: cohort study Participants: 111 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among community-living dyads, a nonpharmacologic biobehavioral environmental intervention compared with control resulted in better outcomes for COPE dyads at 4 months. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this cohort of older adults, increased numbers of optimal cardiovascular health metrics and a higher cardiovascular health score were associated with a lower risk of dementia and lower rates of cognitive decline. 5 key findings →
Design: cohort study Participants: 6,626 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this study, both higher Mediterranean-type diet adherence and higher physical activity were independently associated with reduced risk for AD. 5 key findings →
Design: cohort study Participants: 282 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Progressive dementia was detected by PET with a sensitivity of 93% (191/206) and a specificity of 76% (59/78). 4 key findings →
Design: longitudinal study Participants: 146 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In secondary analyses, the area under the curve (AUC) of [18F]flortaucipir SUVR was compared with 3 established magnetic resonance imaging measures (hippocampal volumes and AD signature and whole-brain cortical thickness), and sensitivity and specificity of [18F]flortaucipir in MCI due to AD vs non-AD neurodegenerative disorders were determined. 3 key findings →
Design: cross-sectional Participants: 719 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Four hundred ninety-four individuals eventually developed dementia and 427 (86%) of these persons were admitted at least once; 2525 remained free of dementia and 1478 (59%) of those were admitted at least once. 4 key findings →
Design: cohort study Participants: 3,019 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During a mean (SD) follow-up of 6.1 (3.2) years, 1601 participants had no hospitalization, 1287 had 1 or more noncritical illness hospitalizations, and 41 had 1 or more critical illness hospitalizations. 4 key findings →
Design: cohort study Participants: 2,929 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →